文献速递脊柱关节炎

中轴型脊柱关节炎缓解后继续与停用伊奇珠单抗:随机撤药研究

Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
PubMed 文献 · Ann Rheum Dis · 2021-05-06

COAST-Y 是一项 III 期长期扩展研究,纳入中轴型脊柱关节炎(axSpA)患者,在 24 周导入期达到缓解后随机分为继续伊奇珠单抗(IXE)Q4W、Q2W 或撤药至安慰剂(PBO)。40 周随机撤药期后,继续 IXE 组无复发比例显著高于 PBO 组,且至复发时间显著延迟。

要点

  • axSpA 缓解后继续 IXE 治疗较撤药至 PBO 显著降低复发风险。
  • 继续 IXE 显著延迟至复发时间,撤药后多数患者至 20 周仍无复发。
  • 撤药至 PBO 组 40 周无复发比例为 54.7%,低于继续 IXE 各组。

核心结论

  • axSpA 患者达到缓解后继续 IXE 治疗较撤药至 PBO 显著减少复发并延迟复发时间。

研究设计与样本

  • COAST-Y 为正在进行的 III 期长期扩展研究,包含双盲、PBO 对照、随机撤药-再治疗期(RWRP)。
  • 完成 52 周 COAST-V、COAST-W 或 COAST-X 的患者进入 24 周导入期,继续 IXE 80 mg Q2W 或 Q4W。
  • 第 24 周达到缓解者按 1:1:1 随机分为继续 IXE Q4W、IXE Q2W 或撤药至 PBO,双盲进行。

主要发现

  • 773 例入组患者中 741 例完成 24 周导入期,155 例进入 RWRP。
  • 40 周 RWRP 后,联合 IXE 组 83.3%(85/102,p<0.001)、IXE Q4W 组 40/48(p=0.003)和 IXE Q2W 组 45/54(p=0.001)保持无复发,PBO 组为 54.7%(29/53)。
  • 继续 IXE 较 PBO 显著延迟至复发时间,多数患者在 IXE 撤药后至 20 周仍无复发。

关键数值与推荐

  • 缓解定义:ASDAS<1.3 至少在第 16 周或第 20 周出现一次,且两次访视均<2.1。
  • 复发定义:连续两次访视 ASDAS≥2.1 或任意访视 ASDAS>3.5。
  • 主要终点为 40 周 RWRP 后无复发患者比例,至复发时间为关键次要终点。

临床怎么用

  • 对已达到缓解的 axSpA 患者,继续 IXE 治疗较撤药可显著降低复发风险并延迟复发。
  • 撤药后多数患者至 20 周仍无复发,提示短期撤药可能可行但需密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of COAST-Y was to evaluate the effect of continuing versus withdrawing ixekizumab (IXE) in patients with axial spondyloarthritis (axSpA) who had achieved remission. METHODS: COAST-Y is an ongoing, phase III, long-term extension study that included a double-blind, placebo (PBO)-controlled, randomised withdrawal-retreatment period (RWRP). Patients who completed the originating 52-week COAST-V, COAST-W or COAST-X studies entered a 24-week lead-in period and continued either 80 mg IXE every 2 (Q2W) or 4 weeks (Q4W). Patients who achieved remission (an Ankylosing Spondylitis Disease Activity Score (ASDAS)<1.3 at least once at week 16 or week 20, and <2.1 at both visits) were randomly assigned equally at week 24 to continue IXE Q4W, IXE Q2W or withdraw to PBO in a blinded fashion. The primary endpoint was the proportion of flare-free patients (flare: ASDAS≥2.1 at two consecutive visits or ASDAS>3.5 at any visit) after the 40-week RWRP, with time-to-flare as a major secondary endpoint. RESULTS: Of 773 enrolled patients, 741 completed the 24-week lead-in period and 155 entered the RWRP. Forty weeks after randomised withdrawal, 83.3% of patients in the combined IXE (85/102, p<0.001), IXE Q4W (40/48, p=0.003) and IXE Q2W (45/54, p=0.001) groups remained flare-free versus 54.7% in the PBO group (29/53). Continuing IXE significantly delayed time-to-flare versus PBO, with most patients remaining flare-free for up to 20 weeks after IXE withdrawal. CONCLUSIONS: Patients with axSpA who continued treatment with IXE were significantly less likely to flare and had significantly delayed time-to-flare compared with patients who withdrew to PBO.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Landewé RB, Gensler LS, Poddubnyy D, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021. PMID: 33958326. doi:10.1136/annrheumdis-2020-219717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。